The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02

Brendon Drew; Jonathan D. Auten; Andrew P. Cap; Travis G. Deaton; Benjamin Donham; Warren C. Dorlac; Joseph J. DuBose; Andrew D. Fisher; Alan J. Ginn; James Hancock; John B. Holcomb; John Knight; Albert Ken Koerner; Lanny F. Littlejohn; Matthew J. Martin; John Kip Morey; Jonathan Morrison; Martin A. Schreiber; Philip C. Spinella; Benjamin Walrath; Frank K. Butler

The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02

Brendon Drew, Jonathan D. Auten, Andrew P. Cap, Travis G. Deaton, Benjamin Donham, Warren C. Dorlac, Joseph J. DuBose, Andrew D. Fisher, Alan J. Ginn, James Hancock, John B. Holcomb, John Knight, Albert Ken Koerner, Lanny F. Littlejohn, Matthew J. Martin, John Kip Morey, Jonathan Morrison, Martin A. Schreiber, Philip C. Spinella, Benjamin WalrathFrank K. Butler

Trauma, Critical Care and Acute Care Surgery

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The literature continues to provide strong support for the early use of tranexamic acid (TXA) in severely injured trauma patients. Questions persist, however, regarding the optimal medical and tactical/logistical use, timing, and dose of this medication, both from the published TXA literature and from the TCCC user community. The use of TXA has been explored outside of trauma, new dosing strategies have been pursued, and expansion of retrospective use data has grown as well. These questions emphasize the need for a reexamination of TXA by the CoTCCC. The most significant updates to the TCCC Guidelines are (i) including significant traumatic brain injury (TBI) as an indication for TXA, (ii) changing the dosing protocol to a single 2g IV/IO administration, and (iii) recommending TXA administration via slow IV/IO push.

Original language	English (US)
Pages (from-to)	36-43
Number of pages	8
Journal	Journal of special operations medicine : a peer reviewed journal for SOF medical professionals
Volume	20
Issue number	3
State	Published - Sep 1 2020

ASJC Scopus subject areas

General Medicine

Cite this

Drew, B., Auten, J. D., Cap, A. P., Deaton, T. G., Donham, B., Dorlac, W. C., DuBose, J. J., Fisher, A. D., Ginn, A. J., Hancock, J., Holcomb, J. B., Knight, J., Koerner, A. K., Littlejohn, L. F., Martin, M. J., Morey, J. K., Morrison, J., Schreiber, M. A., Spinella, P. C., ... Butler, F. K. (2020). The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02. Journal of special operations medicine : a peer reviewed journal for SOF medical professionals, 20(3), 36-43.

Drew, B, Auten, JD, Cap, AP, Deaton, TG, Donham, B, Dorlac, WC, DuBose, JJ, Fisher, AD, Ginn, AJ, Hancock, J, Holcomb, JB, Knight, J, Koerner, AK, Littlejohn, LF, Martin, MJ, Morey, JK, Morrison, J, Schreiber, MA, Spinella, PC, Walrath, B & Butler, FK 2020, 'The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02', Journal of special operations medicine : a peer reviewed journal for SOF medical professionals, vol. 20, no. 3, pp. 36-43.

@article{18da6271a1944e36babd6acebed6ef29,

title = "The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02",

abstract = "The literature continues to provide strong support for the early use of tranexamic acid (TXA) in severely injured trauma patients. Questions persist, however, regarding the optimal medical and tactical/logistical use, timing, and dose of this medication, both from the published TXA literature and from the TCCC user community. The use of TXA has been explored outside of trauma, new dosing strategies have been pursued, and expansion of retrospective use data has grown as well. These questions emphasize the need for a reexamination of TXA by the CoTCCC. The most significant updates to the TCCC Guidelines are (i) including significant traumatic brain injury (TBI) as an indication for TXA, (ii) changing the dosing protocol to a single 2g IV/IO administration, and (iii) recommending TXA administration via slow IV/IO push.",

author = "Brendon Drew and Auten, {Jonathan D.} and Cap, {Andrew P.} and Deaton, {Travis G.} and Benjamin Donham and Dorlac, {Warren C.} and DuBose, {Joseph J.} and Fisher, {Andrew D.} and Ginn, {Alan J.} and James Hancock and Holcomb, {John B.} and John Knight and Koerner, {Albert Ken} and Littlejohn, {Lanny F.} and Martin, {Matthew J.} and Morey, {John Kip} and Jonathan Morrison and Schreiber, {Martin A.} and Spinella, {Philip C.} and Benjamin Walrath and Butler, {Frank K.}",

note = "Publisher Copyright: 2020.",

year = "2020",

month = sep,

day = "1",

language = "English (US)",

volume = "20",

pages = "36--43",

journal = "Journal of special operations medicine : a peer reviewed journal for SOF medical professionals",

issn = "1553-9768",

publisher = "U.S. Special Operations Command",

number = "3",

}

TY - JOUR

T1 - The Use of Tranexamic Acid in Tactical Combat Casualty Care

T2 - TCCC Proposed Change 20-02

AU - Drew, Brendon

AU - Auten, Jonathan D.

AU - Cap, Andrew P.

AU - Deaton, Travis G.

AU - Donham, Benjamin

AU - Dorlac, Warren C.

AU - DuBose, Joseph J.

AU - Fisher, Andrew D.

AU - Ginn, Alan J.

AU - Hancock, James

AU - Holcomb, John B.

AU - Knight, John

AU - Koerner, Albert Ken

AU - Littlejohn, Lanny F.

AU - Martin, Matthew J.

AU - Morey, John Kip

AU - Morrison, Jonathan

AU - Schreiber, Martin A.

AU - Spinella, Philip C.

AU - Walrath, Benjamin

AU - Butler, Frank K.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - The literature continues to provide strong support for the early use of tranexamic acid (TXA) in severely injured trauma patients. Questions persist, however, regarding the optimal medical and tactical/logistical use, timing, and dose of this medication, both from the published TXA literature and from the TCCC user community. The use of TXA has been explored outside of trauma, new dosing strategies have been pursued, and expansion of retrospective use data has grown as well. These questions emphasize the need for a reexamination of TXA by the CoTCCC. The most significant updates to the TCCC Guidelines are (i) including significant traumatic brain injury (TBI) as an indication for TXA, (ii) changing the dosing protocol to a single 2g IV/IO administration, and (iii) recommending TXA administration via slow IV/IO push.

AB - The literature continues to provide strong support for the early use of tranexamic acid (TXA) in severely injured trauma patients. Questions persist, however, regarding the optimal medical and tactical/logistical use, timing, and dose of this medication, both from the published TXA literature and from the TCCC user community. The use of TXA has been explored outside of trauma, new dosing strategies have been pursued, and expansion of retrospective use data has grown as well. These questions emphasize the need for a reexamination of TXA by the CoTCCC. The most significant updates to the TCCC Guidelines are (i) including significant traumatic brain injury (TBI) as an indication for TXA, (ii) changing the dosing protocol to a single 2g IV/IO administration, and (iii) recommending TXA administration via slow IV/IO push.

UR - http://www.scopus.com/inward/record.url?scp=85091551452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091551452&partnerID=8YFLogxK

M3 - Article

C2 - 32969002

AN - SCOPUS:85091551452

SN - 1553-9768

VL - 20

SP - 36

EP - 43

JO - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals

JF - Journal of special operations medicine : a peer reviewed journal for SOF medical professionals

IS - 3

ER -

The Use of Tranexamic Acid in Tactical Combat Casualty Care: TCCC Proposed Change 20-02

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this